The company has reported a PAT of Rs 8.7 crore in the same quarter last year, Hikal said in a statement.
During the period, the company's net sales also increased to Rs 91.9 crore, a rise of 63 per cent against the same period last year.
"The long-term contracts signed earlier with leading global life sciences companies is now resulting in increased pharma sales. We expect this trend to continue as a number of our projects will go on stream in the coming quarters," Hikal Ltd Vice-Chairman and Managing Director Jai Hiremath said.
Hikal is supplying key active ingredients and intermediates, manufactured using global quality standards, for it's customers in the United States, Europe and Japan.